Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation
Background Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated...
Gespeichert in:
| Veröffentlicht in: | Clinical research in cardiology 2015-12, Vol.104 (12), p.1064-1071 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1071 |
|---|---|
| container_issue | 12 |
| container_start_page | 1064 |
| container_title | Clinical research in cardiology |
| container_volume | 104 |
| creator | Dörr, Oliver Ewen, Sebastian Liebetrau, Christoph Möllmann, Helge Gaede, Luise Linz, Dominik Hohl, Mathias Troidl, Christian Bauer, Timm Böhm, Michael Hamm, Christian Mahfoud, Felix Nef, Holger |
| description | Background
Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD.
Methods
A total of 150 consecutive patients (age 64.9 ± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD.
Results
BP and NPY levels were significantly reduced by 23/9 mmHg (
p
= 0.001/0.001) and 0.24 mg/dL (
p
|
| doi_str_mv | 10.1007/s00392-015-0874-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837342149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3872441551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-37aeb045857b958436170a0e8774d0aafc68a02da4bb1bb0a1e2599f213f8c753</originalsourceid><addsrcrecordid>eNqF0cFqFTEUBuAgiq3VB3AjATduRk8mmSSzLKW2QtGNLlyFM5kzmjJ3ZppkChf68Ob21lILxVUC-c6fhJ-xtwI-CgDzKQHItq5ANBVYoyr7jB0Kq0UFuq2f3--tOmCvUroEaARI9ZId1BrA2lYfspuvtMZ5oSWHnvhPjonjxMPUB495jnweeFq9p5SGdeQ4ZoqYwzylYnjabhbMvykHzyeK1_Napn0O1yFvOQ7F8kgTjv_Annb0NuQ1ezHgmOjN3XrEfnw-_X5yXl18O_tycnxReSVtrqRB6kA1tjFd21gltTCAQNYY1QPi4LVFqHtUXSe6DlBQ3bTtUAs5WG8aecQ-7HOXOF-tlLLbhORpHHGi8mYnrDRS1UK1_6dGNlIK0LLQ94_o5bzG8t1bpVqttIaixF75OKcUaXBLDBuMWyfA7Vp0-xZdadHtWnS2zLy7S167DfX3E39rK6Deg1SOpl8UH1z9ZOofDnGpCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1734964660</pqid></control><display><type>article</type><title>Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Dörr, Oliver ; Ewen, Sebastian ; Liebetrau, Christoph ; Möllmann, Helge ; Gaede, Luise ; Linz, Dominik ; Hohl, Mathias ; Troidl, Christian ; Bauer, Timm ; Böhm, Michael ; Hamm, Christian ; Mahfoud, Felix ; Nef, Holger</creator><creatorcontrib>Dörr, Oliver ; Ewen, Sebastian ; Liebetrau, Christoph ; Möllmann, Helge ; Gaede, Luise ; Linz, Dominik ; Hohl, Mathias ; Troidl, Christian ; Bauer, Timm ; Böhm, Michael ; Hamm, Christian ; Mahfoud, Felix ; Nef, Holger</creatorcontrib><description>Background
Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD.
Methods
A total of 150 consecutive patients (age 64.9 ± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD.
Results
BP and NPY levels were significantly reduced by 23/9 mmHg (
p
= 0.001/0.001) and 0.24 mg/dL (
p
< 0.01) 6 months after RSD. There was a significant correlation between baseline SBP- and RSD-related systolic BP reduction (
r
= −0.43;
p
< 0.001) and between serum NPY baseline values and NPY level changes (
r
= −0.52;
p
< 0.001) at the 6-month follow-up. The BP response to RSD (>10 mmHg) was associated with a significantly greater reduction in NPY level when compared with BP non-responders (
p
= 0.001).
Conclusion
This study demonstrates an effect of RSD on serum NPY levels, a specific marker for sympathetic activity. The association between RSD-related changes in SBP and NPY levels provides further evidence of the effect of RSD on the sympathetic nervous system.</description><identifier>ISSN: 1861-0684</identifier><identifier>EISSN: 1861-0692</identifier><identifier>DOI: 10.1007/s00392-015-0874-8</identifier><identifier>PMID: 26008896</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Blood Pressure - physiology ; Cardiology ; Female ; Follow-Up Studies ; Humans ; Hypertension - surgery ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neuropeptide Y - blood ; Original Paper ; Sympathectomy - methods ; Treatment Outcome</subject><ispartof>Clinical research in cardiology, 2015-12, Vol.104 (12), p.1064-1071</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-37aeb045857b958436170a0e8774d0aafc68a02da4bb1bb0a1e2599f213f8c753</citedby><cites>FETCH-LOGICAL-c438t-37aeb045857b958436170a0e8774d0aafc68a02da4bb1bb0a1e2599f213f8c753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00392-015-0874-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00392-015-0874-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26008896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dörr, Oliver</creatorcontrib><creatorcontrib>Ewen, Sebastian</creatorcontrib><creatorcontrib>Liebetrau, Christoph</creatorcontrib><creatorcontrib>Möllmann, Helge</creatorcontrib><creatorcontrib>Gaede, Luise</creatorcontrib><creatorcontrib>Linz, Dominik</creatorcontrib><creatorcontrib>Hohl, Mathias</creatorcontrib><creatorcontrib>Troidl, Christian</creatorcontrib><creatorcontrib>Bauer, Timm</creatorcontrib><creatorcontrib>Böhm, Michael</creatorcontrib><creatorcontrib>Hamm, Christian</creatorcontrib><creatorcontrib>Mahfoud, Felix</creatorcontrib><creatorcontrib>Nef, Holger</creatorcontrib><title>Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation</title><title>Clinical research in cardiology</title><addtitle>Clin Res Cardiol</addtitle><addtitle>Clin Res Cardiol</addtitle><description>Background
Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD.
Methods
A total of 150 consecutive patients (age 64.9 ± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD.
Results
BP and NPY levels were significantly reduced by 23/9 mmHg (
p
= 0.001/0.001) and 0.24 mg/dL (
p
< 0.01) 6 months after RSD. There was a significant correlation between baseline SBP- and RSD-related systolic BP reduction (
r
= −0.43;
p
< 0.001) and between serum NPY baseline values and NPY level changes (
r
= −0.52;
p
< 0.001) at the 6-month follow-up. The BP response to RSD (>10 mmHg) was associated with a significantly greater reduction in NPY level when compared with BP non-responders (
p
= 0.001).
Conclusion
This study demonstrates an effect of RSD on serum NPY levels, a specific marker for sympathetic activity. The association between RSD-related changes in SBP and NPY levels provides further evidence of the effect of RSD on the sympathetic nervous system.</description><subject>Aged</subject><subject>Blood Pressure - physiology</subject><subject>Cardiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypertension - surgery</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neuropeptide Y - blood</subject><subject>Original Paper</subject><subject>Sympathectomy - methods</subject><subject>Treatment Outcome</subject><issn>1861-0684</issn><issn>1861-0692</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0cFqFTEUBuAgiq3VB3AjATduRk8mmSSzLKW2QtGNLlyFM5kzmjJ3ZppkChf68Ob21lILxVUC-c6fhJ-xtwI-CgDzKQHItq5ANBVYoyr7jB0Kq0UFuq2f3--tOmCvUroEaARI9ZId1BrA2lYfspuvtMZ5oSWHnvhPjonjxMPUB495jnweeFq9p5SGdeQ4ZoqYwzylYnjabhbMvykHzyeK1_Napn0O1yFvOQ7F8kgTjv_Annb0NuQ1ezHgmOjN3XrEfnw-_X5yXl18O_tycnxReSVtrqRB6kA1tjFd21gltTCAQNYY1QPi4LVFqHtUXSe6DlBQ3bTtUAs5WG8aecQ-7HOXOF-tlLLbhORpHHGi8mYnrDRS1UK1_6dGNlIK0LLQ94_o5bzG8t1bpVqttIaixF75OKcUaXBLDBuMWyfA7Vp0-xZdadHtWnS2zLy7S167DfX3E39rK6Deg1SOpl8UH1z9ZOofDnGpCA</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Dörr, Oliver</creator><creator>Ewen, Sebastian</creator><creator>Liebetrau, Christoph</creator><creator>Möllmann, Helge</creator><creator>Gaede, Luise</creator><creator>Linz, Dominik</creator><creator>Hohl, Mathias</creator><creator>Troidl, Christian</creator><creator>Bauer, Timm</creator><creator>Böhm, Michael</creator><creator>Hamm, Christian</creator><creator>Mahfoud, Felix</creator><creator>Nef, Holger</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20151201</creationdate><title>Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation</title><author>Dörr, Oliver ; Ewen, Sebastian ; Liebetrau, Christoph ; Möllmann, Helge ; Gaede, Luise ; Linz, Dominik ; Hohl, Mathias ; Troidl, Christian ; Bauer, Timm ; Böhm, Michael ; Hamm, Christian ; Mahfoud, Felix ; Nef, Holger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-37aeb045857b958436170a0e8774d0aafc68a02da4bb1bb0a1e2599f213f8c753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Blood Pressure - physiology</topic><topic>Cardiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypertension - surgery</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neuropeptide Y - blood</topic><topic>Original Paper</topic><topic>Sympathectomy - methods</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dörr, Oliver</creatorcontrib><creatorcontrib>Ewen, Sebastian</creatorcontrib><creatorcontrib>Liebetrau, Christoph</creatorcontrib><creatorcontrib>Möllmann, Helge</creatorcontrib><creatorcontrib>Gaede, Luise</creatorcontrib><creatorcontrib>Linz, Dominik</creatorcontrib><creatorcontrib>Hohl, Mathias</creatorcontrib><creatorcontrib>Troidl, Christian</creatorcontrib><creatorcontrib>Bauer, Timm</creatorcontrib><creatorcontrib>Böhm, Michael</creatorcontrib><creatorcontrib>Hamm, Christian</creatorcontrib><creatorcontrib>Mahfoud, Felix</creatorcontrib><creatorcontrib>Nef, Holger</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Clinical research in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dörr, Oliver</au><au>Ewen, Sebastian</au><au>Liebetrau, Christoph</au><au>Möllmann, Helge</au><au>Gaede, Luise</au><au>Linz, Dominik</au><au>Hohl, Mathias</au><au>Troidl, Christian</au><au>Bauer, Timm</au><au>Böhm, Michael</au><au>Hamm, Christian</au><au>Mahfoud, Felix</au><au>Nef, Holger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation</atitle><jtitle>Clinical research in cardiology</jtitle><stitle>Clin Res Cardiol</stitle><addtitle>Clin Res Cardiol</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>104</volume><issue>12</issue><spage>1064</spage><epage>1071</epage><pages>1064-1071</pages><issn>1861-0684</issn><eissn>1861-0692</eissn><abstract>Background
Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD.
Methods
A total of 150 consecutive patients (age 64.9 ± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD.
Results
BP and NPY levels were significantly reduced by 23/9 mmHg (
p
= 0.001/0.001) and 0.24 mg/dL (
p
< 0.01) 6 months after RSD. There was a significant correlation between baseline SBP- and RSD-related systolic BP reduction (
r
= −0.43;
p
< 0.001) and between serum NPY baseline values and NPY level changes (
r
= −0.52;
p
< 0.001) at the 6-month follow-up. The BP response to RSD (>10 mmHg) was associated with a significantly greater reduction in NPY level when compared with BP non-responders (
p
= 0.001).
Conclusion
This study demonstrates an effect of RSD on serum NPY levels, a specific marker for sympathetic activity. The association between RSD-related changes in SBP and NPY levels provides further evidence of the effect of RSD on the sympathetic nervous system.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>26008896</pmid><doi>10.1007/s00392-015-0874-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1861-0684 |
| ispartof | Clinical research in cardiology, 2015-12, Vol.104 (12), p.1064-1071 |
| issn | 1861-0684 1861-0692 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1837342149 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Blood Pressure - physiology Cardiology Female Follow-Up Studies Humans Hypertension - surgery Male Medicine Medicine & Public Health Middle Aged Neuropeptide Y - blood Original Paper Sympathectomy - methods Treatment Outcome |
| title | Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A57%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuropeptide%20Y%20as%20an%20indicator%20of%20successful%20alterations%20in%20sympathetic%20nervous%20activity%20after%20renal%20sympathetic%20denervation&rft.jtitle=Clinical%20research%20in%20cardiology&rft.au=D%C3%B6rr,%20Oliver&rft.date=2015-12-01&rft.volume=104&rft.issue=12&rft.spage=1064&rft.epage=1071&rft.pages=1064-1071&rft.issn=1861-0684&rft.eissn=1861-0692&rft_id=info:doi/10.1007/s00392-015-0874-8&rft_dat=%3Cproquest_cross%3E3872441551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1734964660&rft_id=info:pmid/26008896&rfr_iscdi=true |